Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
Submitted by
admin
on July 11, 2018 - 10:12am
Source:
CP Wire
News Tags:
Seattle Genetics
tucatinib
orphan drugs
clinical trials
HER2-positive metastatic breast cancer
breast cancer
Headline:
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
snippet:
Tucatinib has been granted orphan drug status for the treatment of breast cancer patients with brain metastases.
Overall response rate (ORR) was 61% for Ph Ib triplet study
Tucatinib was well tolerated both trials
Do Not Allow Advertisers to Use My Personal information
